Scarica l'app Stockscreener
69.70
3.61%
2.43
Dopo l'orario di chiusura:
69.68
-0.02
-0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$67.27
Aprire:
$67.945
Volume 24 ore:
7.92M
Relative Volume:
1.13
Capitalizzazione di mercato:
$27.66B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-8.5561
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+17.45%
1M Prestazione:
+47.70%
6M Prestazione:
+123.76%
1 anno Prestazione:
+156.63%
Intervallo 1D:
$66.30
$69.90
Intervallo di 1 settimana:
$57.91
$69.90
Portata 52W:
$22.28
$69.90
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
69.70 | 26.69B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
499.65 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.81 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.46 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.62 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.52 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines - TradingView
Stock Of The Day: Will The Moderna Rally Continue? - Benzinga
Moderna (MRNA) Stock Soars 13% on Groundbreaking CAR-T Program Announcement - Blockonomi
Moderna (NASDAQ:MRNA) surge puts stock above most analyst targets ahead of FDA review - TechStock²
Patton Fund Management Inc. Has $4.49 Million Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna Stock Jumps 12% as Pipeline Reset Puts Aug. 5 FDA Catalyst in Focus - FXLeaders
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA - Stocktwits
Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week - TechStock²
Moderna (MRNA) Stock Soars 13% on In Vivo CAR-T Breakthrough and Flu Vaccine Progress - Blockonomi
SG Americas Securities LLC Sells 27,930 Shares of Moderna, Inc. $MRNA - MarketBeat
The mRESVIA from Moderna Inc.RSV protection moves beyond Covid - Ad-hoc-news.de
S&P 500 ends lower; chips tumble and Moderna rallies - Yahoo Finance
MRNA Stock Surges As Flu Win And Pipeline Shift Grab Attention - timothysykes.com
Wall Street ends mixed; chips tumble and Moderna rallies - marketscreener.com
Trending: Netflix stock bounces back, Moderna surges post–investor day, ON Semi plummets - Yahoo Finance
Moderna stock soars as cancer pipeline and CAR-T push ignite optimism - Invezz
MRNA Maintained by Piper Sandler -- Price Target Raised to $77.0 - GuruFocus
Moderna Shares Up on New Research Efforts for Autoimmune Disorder - WSJ
Wall Street mixed as Moderna rallies and chips tumble - marketscreener.com
Moderna (MRNA) Shares Surge 15% Following Major Business Update - GuruFocus
Why Moderna Is Today’s Top S&P 500 Stock - Barron's
Moderna stock soars 15% as bulls cheer drug pipeline update: Next stop $75? - MSN
Moderna (NASDAQ:MRNA) Reaches New 12-Month HighHere's Why - MarketBeat
Moderna (MRNA) Sees 14.2% Surge, Reaches $68.23 - GuruFocus
Moderna (NASDAQ:MRNA) gains $3.3 billion after CAR-T update - TechStock²
MRNA Stock Jumps As Flu Win And Pipeline Story Heat Up - StocksToTrade
Moderna jumps 12% after investor day - Breakingthenews.net
Moderna highlights expanding mRNA platform at Science Day - Clinical Trials Arena
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer? - Yahoo Finance
MRNA Stock Jumps As Flu Win And Pipeline Reset Ignite Momentum - timothysykes.com
Moderna stock hits 52-week high at $67.78 By Investing.com - Investing.com Canada
Moderna stock hits 52-week high at $67.78 - Investing.com
Moderna (MRNA) Sees 8.7% Gain, Closing at $64.95 - GuruFocus
Piper Sandler raises Moderna stock price target on pipeline progress - Investing.com
Piper Sandler raises Moderna stock price target on pipeline progress By Investing.com - Investing.com Canada
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms - BioSpace
Moderna shows in vivo CAR-T hand in R&D update - pharmaphorum
Jefferies Adjusts Price Target on Moderna to $53 From $45, Maintains Hold Rating - marketscreener.com
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst - The Globe and Mail
FDA Panel Backs Moderna’s mRNA-Based Influenza Vaccine for Adults 50+ - Infectious Disease Advisor
Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh - TradingView
Moderna, Inc. Stock 12‑Month Price Target Raised to $47.45, Implies 21% Downside - TradingView
Moderna Upbeat on New Flu Shot to Help Educate Public About MRNA - Bloomberg
Moderna outlines next phase of mRNA expansion beyond vaccines - The Pharma Letter
Price to book forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
Moderna, Inc. Actuals & Estimates (NASDAQ:MRNA) - TradingView
Enterprise value to EBIT forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
Moderna Science Day Highlights Expanding Potential of mRNA Platform - Investing News Network
Moderna (MRNA) Unveils Strategic Development Goals at Science Da - GuruFocus
Moderna updates pipeline with CAR-T program for autoimmune diseases By Investing.com - Investing.com Canada
Enterprise value to EBITDA forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):